- Report
- October 2024
- 196 Pages
Global
From €3238EUR$3,545USD£2,769GBP
€3598EUR$3,939USD£3,076GBP
- Report
- April 2025
- 363 Pages
Global
From €4978EUR$5,450USD£4,257GBP
- Drug Pipelines
- March 2025
- 280 Pages
Global
From €2740EUR$3,000USD£2,343GBP
- Report
- August 2024
- 150 Pages
Global
From €3534EUR$3,869USD£3,022GBP
- Report
- June 2021
- 50 Pages
China
From €2375EUR$2,600USD£2,031GBP
- Clinical Trials
- April 2024
- 550 Pages
Global
From €4567EUR$5,000USD£3,905GBP
- Report
- February 2022
- 308 Pages
Global
From €8677EUR$9,500USD£7,420GBP
- Report
- June 2022
- 117 Pages
Global
From €4338EUR$4,750USD£3,710GBP
- Report
- February 2024
- 91 Pages
Global
From €3500EUR$4,105USD£3,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2420EUR$2,650USD£2,070GBP
- Report
- August 2024
- 199 Pages
China
From €3653EUR$4,000USD£3,124GBP
- Report
- August 2024
- 98 Pages
China
From €1644EUR$1,800USD£1,406GBP

Oxaliplatin is a chemotherapy drug used to treat colon cancer. It is a platinum-based drug, meaning it works by interfering with the growth of cancer cells. Oxaliplatin is often used in combination with other drugs, such as 5-fluorouracil and leucovorin, to create a more effective treatment. It is typically administered intravenously, and is used to treat both early and advanced stages of colon cancer.
Oxaliplatin is a relatively new drug, having been approved by the FDA in 2002. It has become a popular treatment option due to its effectiveness and relatively low side effects. Common side effects include nausea, vomiting, and fatigue.
The Oxaliplatin market is highly competitive, with many companies offering their own versions of the drug. Some of the major players in the market include Sanofi, Pfizer, Merck, and Bristol-Myers Squibb. Show Less Read more